Beta Bionics filings document a Nasdaq-listed medical device issuer commercializing diabetes-management technology for insulin-requiring people. Recent Form 8-K reports provide results of operations, financial condition, guidance-related exhibits, channel metrics for Durable Medical Equipment and Pharmacy Benefit Plan reimbursement, and disclosures tied to iLet Bionic Pancreas data and investor presentations.
The company’s proxy materials cover annual meeting matters, board-class director elections, auditor ratification, voting mechanics, and stockholder governance. Other material-event filings disclose FDA inspection correspondence involving Quality Management System, Medical Device Reporting, and Corrections and Removals, alongside the company’s registered common stock and public-company reporting status.
Beta Bionics reported that it received a warning letter from the U.S. FDA on January 29, 2026 following an inspection of its Irvine, California facility conducted in June 2025. The FDA cited deficiencies in the company’s responses to a prior Form 483 and highlighted non-conformities in its quality system, medical device reporting, and correction and removal processes.
The letter does not currently limit Beta Bionics’ ability to manufacture, market, or distribute products, or to seek FDA 510(k) clearance for new products. The company has begun corrective actions, is preparing a written response, and plans ongoing updates to the FDA, but notes that additional regulatory action is possible until issues are resolved. Beta Bionics states it does not expect this warning letter to materially affect its previously disclosed guidance to launch commercialization of Mint by the end of 2027.
Beta Bionics, Inc. director Michel Gerard reported receiving an award of 3,997 shares of common stock on 01/13/2026. The filing shows this as an automatic acquisition at a price of $0 per share, representing a restricted stock unit grant under the company’s 2025 Equity Incentive Plan. Following this award, Gerard beneficially owns 16,544 shares of Beta Bionics common stock in direct form.
Beta Bionics, Inc. director Sean Carney reported a stock-based award. On 01/13/2026, he acquired 3,997 shares of common stock at a price of $0, described as a restricted stock unit award granted under the company’s 2025 Equity Incentive Plan. After this grant, he beneficially owned 15,244 shares of Beta Bionics common stock, held directly.
Beta Bionics, Inc. director Maria Palasis reported receiving a grant of 3,997 shares of common stock on January 13, 2026. The transaction is coded as an acquisition at a price of $0 per share and is described as a restricted stock unit award granted under the company’s 2025 Equity Incentive Plan. Following this award, Palasis beneficially owns 12,432 shares of Beta Bionics common stock, held in direct ownership.
Beta Bionics, Inc. director Christy Jones reported an equity award on a Form 4. On January 13, 2026, Jones acquired 3,997 shares of common stock with a transaction code "A," indicating an award rather than an open-market purchase, at a stated price of $0 per share.
The footnote explains this represents a restricted stock unit award granted under the company’s 2025 Equity Incentive Plan. Following this grant, Jones beneficially owns 15,244 shares of Beta Bionics common stock in direct ownership.
Beta Bionics, Inc. director Adam Lezack reported an equity award of 3,997 shares of common stock. The Form 4 shows that on January 13, 2026, he acquired 3,997 shares at a price of $0 per share, reflecting a grant rather than an open-market purchase. A footnote explains that this represents a restricted stock unit award granted under the company’s 2025 Equity Incentive Plan. Following this grant, Lezack beneficially owns 12,432 shares of Beta Bionics common stock, held directly.
Beta Bionics, Inc. director Danny L. Dearen reported an equity award of 3,997 shares of common stock. The Form 4 shows the shares were acquired on January 13, 2026 with a transaction code "A", indicating an award or grant rather than an open‑market purchase.
According to the footnote, the grant represents a restricted stock unit award issued under the company’s 2025 Equity Incentive Plan at a stated price of $0 per share, which is typical for RSU grants. After this transaction, Dearen beneficially owns 15,244 shares of Beta Bionics common stock, held directly.
Beta Bionics, Inc. filed a current report to disclose that it has issued a press release with preliminary, unaudited fourth quarter 2025 topline financial results and key operating metrics. The company furnished this information under its results of operations and financial condition disclosure and attached the press release as Exhibit 99.1. The report clarifies that these materials are being furnished rather than filed, which affects how they are treated under securities law.
Beta Bionics, Inc. Chief Product Officer Mike Mensinger reported a planned sale of company stock. On January 6, 2026, he sold 2,200 shares of common stock at a weighted average price of $30.1005 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on September 8, 2025. After this transaction, he beneficially owned 80,752 shares of Beta Bionics common stock directly. The filing notes that individual sale prices ranged between $30.00 and $30.13, and detailed breakdowns are available to regulators, the company, or its security holders on request.
Beta Bionics (BBNX) insider activity: A director reported open-market sales of common stock on 10/31/2025 made under a Rule 10b5-1 plan adopted on July 31, 2025. The filings show two transactions: 1,368 shares sold at a weighted average price of $26.8474 (with individual sale prices ranging from $26.27 to $27.24), and 38 shares sold at $27.70.
Following these sales, the reporting person beneficially owned 9,841 shares, held directly. The form notes that full breakdowns of the number of shares sold at each separate price within the weighted-average transaction are available upon request.